Evolving management of patients treated by drug-eluting stent: Prevention of late events
Summary: Drug eluting stents (DES) were introduced in clinical practice to overcome the problem of in-stent restenosis (ISR) that limited the overall efficacy of percutaneous coronary revascularization with bare metal stent (BMS). Long-term outcome data confirm a sustained benefit of DES as compared...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2014
|
| _version_ | 1826259687503298560 |
|---|---|
| author | Niccoli, G Sgueglia, G Montone, R Roberto, M Banning, A Crea, F |
| author_facet | Niccoli, G Sgueglia, G Montone, R Roberto, M Banning, A Crea, F |
| author_sort | Niccoli, G |
| collection | OXFORD |
| description | Summary: Drug eluting stents (DES) were introduced in clinical practice to overcome the problem of in-stent restenosis (ISR) that limited the overall efficacy of percutaneous coronary revascularization with bare metal stent (BMS). Long-term outcome data confirm a sustained benefit of DES as compared with BMS. However, this benefit is mainly evident in the first year of follow-up. Indeed, DES-related events may extend over this time, due to late events (late ISR and/or very late stent thrombosis). Prevention of late failure of DES may become a specific therapeutic target. © 2014 Elsevier Inc. |
| first_indexed | 2024-03-06T18:53:44Z |
| format | Journal article |
| id | oxford-uuid:111fa77e-ed51-419d-a8d3-2f85be5877f9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:53:44Z |
| publishDate | 2014 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:111fa77e-ed51-419d-a8d3-2f85be5877f92022-03-26T10:00:28ZEvolving management of patients treated by drug-eluting stent: Prevention of late eventsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:111fa77e-ed51-419d-a8d3-2f85be5877f9EnglishSymplectic Elements at OxfordElsevier2014Niccoli, GSgueglia, GMontone, RRoberto, MBanning, ACrea, FSummary: Drug eluting stents (DES) were introduced in clinical practice to overcome the problem of in-stent restenosis (ISR) that limited the overall efficacy of percutaneous coronary revascularization with bare metal stent (BMS). Long-term outcome data confirm a sustained benefit of DES as compared with BMS. However, this benefit is mainly evident in the first year of follow-up. Indeed, DES-related events may extend over this time, due to late events (late ISR and/or very late stent thrombosis). Prevention of late failure of DES may become a specific therapeutic target. © 2014 Elsevier Inc. |
| spellingShingle | Niccoli, G Sgueglia, G Montone, R Roberto, M Banning, A Crea, F Evolving management of patients treated by drug-eluting stent: Prevention of late events |
| title | Evolving management of patients treated by drug-eluting stent: Prevention of late events |
| title_full | Evolving management of patients treated by drug-eluting stent: Prevention of late events |
| title_fullStr | Evolving management of patients treated by drug-eluting stent: Prevention of late events |
| title_full_unstemmed | Evolving management of patients treated by drug-eluting stent: Prevention of late events |
| title_short | Evolving management of patients treated by drug-eluting stent: Prevention of late events |
| title_sort | evolving management of patients treated by drug eluting stent prevention of late events |
| work_keys_str_mv | AT niccolig evolvingmanagementofpatientstreatedbydrugelutingstentpreventionoflateevents AT sguegliag evolvingmanagementofpatientstreatedbydrugelutingstentpreventionoflateevents AT montoner evolvingmanagementofpatientstreatedbydrugelutingstentpreventionoflateevents AT robertom evolvingmanagementofpatientstreatedbydrugelutingstentpreventionoflateevents AT banninga evolvingmanagementofpatientstreatedbydrugelutingstentpreventionoflateevents AT creaf evolvingmanagementofpatientstreatedbydrugelutingstentpreventionoflateevents |